Get the Stockscreener App
78.72
1.16%
0.90
After Hours:
78.85
0.13
+0.17%
Apogee Therapeutics Inc stock is traded at $78.72, with a volume of 987.79K.
It is up +1.16% in the last 24 hours and up +12.46% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$77.82
Open:
$78.04
24h Volume:
987.79K
Relative Volume:
0.93
Market Cap:
$5.87B
Revenue:
-
Net Income/Loss:
$-255.84M
P/E Ratio:
-18.68
EPS:
-4.2149
Net Cash Flow:
$-232.60M
1W Performance:
-0.66%
1M Performance:
+12.46%
6M Performance:
+97.64%
1Y Performance:
+98.19%
1-Day Range:
$76.60
$79.94
1-Week Range:
$71.39
$85.04
52-Week Range:
$26.20
$85.04
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
78.72 | 5.81B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
443.16 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.29 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
704.31 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.09 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.32 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - Investing.com
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target By Investing.com - Investing.com UK
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - marketbeat.com
Mizuho raises Apogee Therapeutics stock price target on AD data - Investing.com
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110 - Moomoo
Apogee Therapeutics announces $300 million public offering - MSN
Wolfe Research initiates coverage of Apogee Therapeutics (APGE) with peer perform recommendation - MSN
Insider Sell Alert: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) price target increased by 11.74% to 118.86 - MSN
Apogee Therapeutics CFO Henderson sells $170k in stock By Investing.com - Investing.com Australia
Apogee Therapeutics CFO Henderson sells $170k in stock - Investing.com
Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data - Yahoo Finance
Apogee Therapeutics (APGE) CFO sells 2,000 shares in planned trade - Stock Titan
Fairmount Funds reveals near-10% Apogee Therapeutics (APGE) stake and 60-day lock-up - Stock Titan
Apogee Therapeutics raises $403 million in stock offering By Investing.com - Investing.com India
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Apogee Therapeutics raises $403 million in stock offering - investing.com
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times
Vanguard disaggregates holdings; Apogee Therapeutics (NASDAQ: APGE) shows 0 shares - Stock Titan
Biotech Apogee raises $403M after underwriters buy extra shares - Stock Titan
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors - The Motley Fool
Apogee Therapeutics stock hits all-time high at 84.56 USD By Investing.com - Investing.com Australia
Apogee Therapeutics Prices Upsized Public Equity Offering - TipRanks
Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week HighHere's Why - marketbeat.com
Apogee Therapeutics announces $377.4 million public offering of common stock - Investing.com Australia
Apogee Therapeutics announces $377.4 million public offering of common stock By Investing.com - Investing.com South Africa
Apogee Therapeutics Prices 5.75 Million-Share Offering at $70, Expecting $377.4 Million Net - TradingView
Apogee Therapeutics (NASDAQ: APGE) raises $329M in 5M-share offering - Stock Titan
[8-K] Apogee Therapeutics, Inc. Reports Material Event - Stock Titan
Jane Henderson sells 6,000 APGE restricted shares (NASDAQ: APGE) - Stock Titan
Apogee Therapeutics shares are trading higher... - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Sees Unusually-High Trading Volume on Analyst Upgrade - marketbeat.com
Latest APGE NewsApogee Highlights Corporate Progress and Re... - Stock Titan
Biotech Apogee sells 5 million shares at $70 to raise $350M - Stock Titan
Rally Mode: Is Apogee Therapeutics Inc attractive for institutional investors2026 Sector Moves & AI Driven Price Forecasts - baoquankhu1.vn
Apogee Therapeutics prices $350 million stock offering at $70 By Investing.com - Investing.com South Africa
Apogee Therapeutics Prices $350 Million Share Offering - marketscreener.com
APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - Bitget
Apogee Therapeutics prices $350 million stock offering at $70 - Investing.com
Apogee Therapeutics, Inc. Prices Public Offering of 5 Million Shares at $70.00 Per Share, Anticipating $350 Million in Gross Proceeds - Quiver Quantitative
Apogee Therapeutics prices $350 million underwritten public offering at $70.00 per share - marketscreener.com
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):